Phio Pharmaceuticals Corp.
Long
Mis à jour

PHIO - long - run up into preclinical data release

233
Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others.

This is not a financial advice!

1 upcoming catalyst on 21st of March 2024

We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.

Shs. Float of 2.4

Keep an eye on 1.35 level, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains.

SL under 0.85

TP approx. 2.10 maybe even 3.0

Most info on the chart.

Trade carefully!
Trade fermée: ordre d’arrêt atteint

Clause de non-responsabilité

Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.